An early and favorable decision is earnestly solicited.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: _____

Robert J. Paradiso
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
Tel. (212) 736-1940

MARKED-UP VERSION TO SHOW CHANGES MADE

IN THE SPECIFICATION

At page 1, please amend the tittle of the invention as follows:

ANALGESIC COMBINATION OF OXYCODONE AND **[T-614] N-[3-(FORMYLAMINO)-4-OXO-6-PHENOXY-4H-1-BENZOPYRAN-7-YL] METHANESULFONAMIDE.**

IN THE CLAIMS

30. (Amended) A pharmaceutical composition comprising an analgesic combination consisting essentially of **[T-614] N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof;** and oxycodone **and/or at least one pharmaceutically acceptable salt thereof.**

31. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** would be sub-therapeutic if administered without the **[T-614] N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof.**

32. (Amended) The pharmaceutical composition according to claim 30, wherein the oxycodone **and/or at least one pharmaceutically acceptable salt thereof;** and **[T-614] N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** are administered orally, via implant, parenterally, sublingually, rectally, topically, or via inhalation.

35. (Amended) The pharmaceutical composition according to claim 30, wherein the ratio of oxycodone **and/or at least one pharmaceutically acceptable salt thereof** to [T-614] **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** is from about 0.0001:1 to about 1:1.

36. (Amended) The pharmaceutical composition according to claim 30, wherein the [T-614] **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** synergistically potentiates the effect of the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** but the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** does not synergistically potentiate the effect of the [T-614] **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof.**

37. (Amended) The pharmaceutical composition according to claim 34, wherein the oral dosage form includes a sustained release carrier which causes the sustained release of the [T-614] **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof;** the oxycodone **and/or at least one pharmaceutically acceptable salt thereof;** or both the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** and the [T-614] **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** when the dosage form contacts gastrointestinal fluid.

38. (Amended) A method of effectively treating pain in humans or other mammals, comprising administering to a patient an analgesic combination consisting essentially of **[T-614] N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof;** and oxycodone **and/or at least one pharmaceutically acceptable salt thereof** such that the dosing interval of the **[T-614] N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** overlaps with the dosing interval of the oxycodone **and/or at least one pharmaceutically acceptable salt thereof.**

39. (Amended) The method of claim 38, wherein the **[T-614] N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salts thereof** and the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** are administered orally.

40. (Amended) The method of claim 38, wherein the **[T-614] N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** and the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** are administered in a single oral dosage form.

41. (Amended) The method of claim 38, wherein the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** would be sub-therapeutic if administered without the **[T-614] N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof.**

42. (Amended) The method of claim 38, wherein the **[T-614]** **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** is administered before, simultaneously with, or after administration of the oxycodone **and/or at least one pharmaceutically acceptable salt thereof**, such that the dosing interval of the **[T-614]** **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** overlaps with the dosing interval of the oxycodone **and/or at least one pharmaceutically acceptable salt thereof.**

43. (Amended) A method of reducing the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** required to treat a patient affected with pain, comprising co-administering said oxycodone **and/or at least one pharmaceutically acceptable salt thereof** with **[said T-614]** **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof,** to augment the analgesia attributable to said oxycodone **and/or at least one pharmaceutically acceptable salt thereof** during at least a portion of the dosage interval of said oxycodone **and/or at least one pharmaceutically acceptable salt thereof.**

44. (Amended) A method of reducing the amount of **[T-614]** **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** required to treat a patient affected with pain comprising co-administering said **[T-614]** **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** with an effective amount of oxycodone **and/or at least one pharmaceutically acceptable salt thereof**, to augment the analgesia attributable to said **[T-614]** **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** during at least a portion of the dosage interval of said **[T-614]** **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof.**

45. (Amended) The pharmaceutical composition according to claim **[1]** **30**, wherein the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** is present in an amount from about 2.5 mg to about 800 mg.

46. (Amended) The method of claim 38, wherein the oxycodone **and/or at least one pharmaceutically acceptable salt thereof** is present in an amount from about 2.5 mg to about 800 mg.

47. (Amended) The method of claim 38, wherein the ratio of oxycodone **and/or at least one pharmaceutically acceptable salt thereof** to **[T-614]** **N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl] methanesulfonamide and/or at least one pharmaceutically acceptable salt thereof** is from about 0.0001:1 to about 1:1.